NASDAQ: BGLCBionexus Gene Lab Corp Stock
$0.59+0.00 (+0%)
Updated Apr 26, 2024
BGLC Price
$0.59
Fair Value Price
N/A
Market Cap
$10.49M
52 Week Low
$0.31
52 Week High
$9.49
P/E
-3.25x
P/B
1.09x
P/S
0.86x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.77M
Earnings
-$2.63M
Gross Margin
13.6%
Operating Margin
-26.54%
Profit Margin
-26.9%
Debt to Equity
0.18
Operating Cash Flow
-$1M
Beta
6.93
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BGLC Overview
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BGLC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BGLC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BGLC is good value based on its book value relative to its share price (1.09x), compared to the US Diagnostics & Research industry average (4.18x)
P/B vs Industry Valuation
BGLC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BGLC due diligence checks available for Premium users.
Be the first to know about important BGLC news, forecast changes, insider trades & much more!
BGLC News
Valuation
BGLC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.25x
Industry
38.49x
Market
41.14x
BGLC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.09x
Industry
4.18x
BGLC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BGLC's financial health
Profit margin
Revenue
$2.3M
Net Income
$308.5k
Profit Margin
13.6%
BGLC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BGLC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$11.4M
Liabilities
$1.7M
Debt to equity
0.18
BGLC's short-term assets ($8.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BGLC's short-term assets ($8.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BGLC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BGLC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$261.9k
Investing
-$13.8k
Financing
$11.1k
BGLC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BGLC vs Diagnostic & Research Stocks
Bionexus Gene Lab Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.